{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:34:54Z","timestamp":1768883694412,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1538,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1365-2036.2011.04730.x","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T22:59:16Z","timestamp":1308351556000},"page":"432-442","source":"Crossref","is-referenced-by-count":95,"title":["Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome"],"prefix":"10.1111","volume":"34","author":[{"given":"P.","family":"Clav\u00e9","sequence":"first","affiliation":[]},{"given":"M.","family":"Acalovschi","sequence":"additional","affiliation":[]},{"given":"J. K.","family":"Triantafillidis","sequence":"additional","affiliation":[]},{"given":"Y. P.","family":"Uspensky","sequence":"additional","affiliation":[]},{"given":"C.","family":"Kalayci","sequence":"additional","affiliation":[]},{"given":"V.","family":"Shee","sequence":"additional","affiliation":[]},{"given":"J.","family":"Tack","sequence":"additional","affiliation":[]},{"name":"on behalf of the OBIS Study Investigators","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2011,6,16]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1046\/j.1365-2036.2002.01305.x","article-title":"Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome","volume":"16","author":"Camilleri","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MCG.0b013e31815bd749","article-title":"Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar","volume":"43","author":"Dorn","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/j.1572-0241.2008.02066.x","article-title":"Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits","volume":"103","author":"Kanazawa","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB7|cit7","first-page":"337","article-title":"Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis","volume":"13","author":"Ford","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1365-2036.2004.02267.x","article-title":"Meta-analysis: the treatment of irritable bowel syndrome","volume":"20","author":"Lesbros-Pantoflickova","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1365-2036.1998.00397.x","article-title":"Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study","volume":"12","author":"Battaglia","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","article-title":"Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome","volume":"15","author":"Poynard","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1111\/j.1365-2982.2010.01495.x","article-title":"Effect of otilonium bromide on contractile patterns in the human sigmoid colon","volume":"22","author":"Gallego","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0928-4257(01)00020-1","article-title":"Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome","volume":"95","author":"Czimmer","year":"2001","journal-title":"J Physiol Paris"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","article-title":"Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective","volume":"24","author":"Tack","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB14|cit14","unstructured":"Committee for Proprietary Medicinal Products (CPMP) Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00042737-200212000-00008","article-title":"Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome","volume":"14","author":"Glende","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"G706","DOI":"10.1152\/ajpgi.00437.2009","article-title":"T-type Ca(2+) channel modulation by otilonium bromide","volume":"298","author":"Strege","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/030006059902700501","article-title":"Otilonium bromide: a selective spasmolytic for the gastrointestinal tract","volume":"27","author":"Evangelista","year":"1999","journal-title":"J Int Med Res"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0090-9556(24)15142-2","article-title":"A distribution study with 14C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration","volume":"28","author":"Evangelista","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2007.07.024","article-title":"Altered rectal perception in irritable bowel syndrome is associated with symptom severity","volume":"133","author":"Posserud","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280050302","article-title":"The clinical pharmacology of single doses of otilonium bromide in healthy volunteers","volume":"52","author":"Sutton","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01318114","article-title":"Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide","volume":"31","author":"Narducci","year":"1986","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.3748\/wjg.v13.i25.3425","article-title":"Placebo responses in patients with gastrointestinal disorders","volume":"13","author":"Musial","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04730.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pain.2006.08.001","article-title":"Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients","volume":"127","author":"Price","year":"2007","journal-title":"Pain"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04730.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04730.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:28:45Z","timestamp":1741249725000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04730.x"}},"subtitle":["Randomised clinical trial: otilonium bromide in IBS"],"short-title":[],"issued":{"date-parts":[[2011,6,16]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04730.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,16]]}}}